Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis : A retrospective study
Copyright © 2021 Elsevier Ltd. All rights reserved..
BACKGROUND: Incidence of thrombotic events associated to Coronavirus disease-2019 (COVID-19) is difficult to assess and reported rates differ significantly. Optimal thromboprophylaxis is unclear.
OBJECTIVES: We aimed to analyze the characteristics of patients with a confirmed thrombotic complication including inflammatory and hemostatic parameters, compare patients affected by arterial vs venous events and examine differences between survivors and non-survivors. We reviewed compliance with thromboprophylaxis and explored how the implementation of a severity-adjusted protocol could have influenced outcome.
METHODS: Single-cohort retrospective study of COVID-19 patients admitted, from March 3 to May 3 2020, to the Infanta Leonor University Hospital in Madrid, epicenter of the Spanish outbreak.
RESULTS: Among 1127 patients, 80 thrombotic events were diagnosed in 69 patients (6.1% of the entire cohort). Forty-three patients (62%) suffered venous thromboembolism, 18 (26%) arterial episodes and 6 (9%) concurrent venous and arterial thrombosis. Most patients (90%) with a confirmed thrombotic complication where under low-molecular-weight heparin treatment. Overt disseminated intravascular coagulation (DIC) was rare. Initial ISTH DIC score and pre-event CRP were significantly higher among non-survivors. In multivariate analysis, arterial localization was an independent predictor of mortality (OR = 18, 95% CI: 2.4-142, p < .05).
CONCLUSIONS: Despite quasi-universal thromboprophylaxis, COVID-19 lead to a myriad of arterial and venous thrombotic events. Considering the subgroup of patients with thrombotic episodes, arterial events appeared earlier in the course of disease and conferred very poor prognosis, and an ISTH DIC score ≥ 3 at presentation was identified as a potential predictor of mortality. Severity-adjusted thromboprophylaxis seemed to decrease the number of events and could have influenced mortality. Randomized controlled trials are eagerly awaited.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:199 |
|---|---|
| Enthalten in: |
Thrombosis research - 199(2021) vom: 15. März, Seite 132-142 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Muñoz-Rivas, Nuria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 18.03.2021 Date Revised 16.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.thromres.2020.12.024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320653234 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320653234 | ||
| 003 | DE-627 | ||
| 005 | 20231225174035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.thromres.2020.12.024 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320653234 | ||
| 035 | |a (NLM)33503547 | ||
| 035 | |a (PII)S0049-3848(21)00001-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Muñoz-Rivas, Nuria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis |b A retrospective study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2021 | ||
| 500 | |a Date Revised 16.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Incidence of thrombotic events associated to Coronavirus disease-2019 (COVID-19) is difficult to assess and reported rates differ significantly. Optimal thromboprophylaxis is unclear | ||
| 520 | |a OBJECTIVES: We aimed to analyze the characteristics of patients with a confirmed thrombotic complication including inflammatory and hemostatic parameters, compare patients affected by arterial vs venous events and examine differences between survivors and non-survivors. We reviewed compliance with thromboprophylaxis and explored how the implementation of a severity-adjusted protocol could have influenced outcome | ||
| 520 | |a METHODS: Single-cohort retrospective study of COVID-19 patients admitted, from March 3 to May 3 2020, to the Infanta Leonor University Hospital in Madrid, epicenter of the Spanish outbreak | ||
| 520 | |a RESULTS: Among 1127 patients, 80 thrombotic events were diagnosed in 69 patients (6.1% of the entire cohort). Forty-three patients (62%) suffered venous thromboembolism, 18 (26%) arterial episodes and 6 (9%) concurrent venous and arterial thrombosis. Most patients (90%) with a confirmed thrombotic complication where under low-molecular-weight heparin treatment. Overt disseminated intravascular coagulation (DIC) was rare. Initial ISTH DIC score and pre-event CRP were significantly higher among non-survivors. In multivariate analysis, arterial localization was an independent predictor of mortality (OR = 18, 95% CI: 2.4-142, p < .05) | ||
| 520 | |a CONCLUSIONS: Despite quasi-universal thromboprophylaxis, COVID-19 lead to a myriad of arterial and venous thrombotic events. Considering the subgroup of patients with thrombotic episodes, arterial events appeared earlier in the course of disease and conferred very poor prognosis, and an ISTH DIC score ≥ 3 at presentation was identified as a potential predictor of mortality. Severity-adjusted thromboprophylaxis seemed to decrease the number of events and could have influenced mortality. Randomized controlled trials are eagerly awaited | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Coronavirus infections | |
| 650 | 4 | |a Disseminated intravascular coagulation | |
| 650 | 4 | |a Heparin, low-molecular-weight | |
| 650 | 4 | |a Thrombophilia | |
| 650 | 4 | |a Thrombosis | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 700 | 1 | |a Abad-Motos, Ane |e verfasserin |4 aut | |
| 700 | 1 | |a Mestre-Gómez, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Sierra-Hidalgo, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Cortina-Camarero, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Lorente-Ramos, Rosa María |e verfasserin |4 aut | |
| 700 | 1 | |a Torres-Rubio, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Arranz-García, Paz |e verfasserin |4 aut | |
| 700 | 1 | |a Franco-Moreno, Ana Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Mariscal, Eloy |e verfasserin |4 aut | |
| 700 | 1 | |a Mauleón-Fernández, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-García, Soledad |e verfasserin |4 aut | |
| 700 | 1 | |a Rogado, Jacobo |e verfasserin |4 aut | |
| 700 | 1 | |a Saez-Vaquero, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Such-Diaz, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Ryan, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Moya-Mateo, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Navarro, Juan A |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Rivas, Jose Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Torres-Macho, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Churruca, Juan |e verfasserin |4 aut | |
| 700 | 0 | |a Infanta Leonor Thrombosis Research Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis research |d 1974 |g 199(2021) vom: 15. März, Seite 132-142 |w (DE-627)NLM000010839 |x 1879-2472 |7 nnns |
| 773 | 1 | 8 | |g volume:199 |g year:2021 |g day:15 |g month:03 |g pages:132-142 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.thromres.2020.12.024 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 199 |j 2021 |b 15 |c 03 |h 132-142 | ||